Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Adjuvant Trastuzumab Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

This randomized clinical trial compares two systemic treatments for HER2-positive breast cancer. The treatments are given either prior to breast surgery (as neoadjuvant treatment) or after breast surgery (as adjuvant treatment). In the investigational group (Group A) the study participants will receive a combination of two drugs directed at HER2 …

her2/neu-positive breast cancer
immunohistochemistry
docetaxel
immunostimulant
cish
  • 7 views
  • 04 Nov, 2020
  • 1 location
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in

tubal ligation
cyclophosphamide
progesterone receptor
paclitaxel
residual tumor
  • 17 views
  • 24 Jan, 2021
  • 48 locations
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).

primary tumor
docetaxel
progesterone receptor
carcinoma
estrogen receptor
  • 0 views
  • 24 Jan, 2021
  • 1 location
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2

progesterone receptor
epidermal growth factor receptor
estrogen receptor
epidermal growth factor
erbb2
  • 0 views
  • 24 Jan, 2021
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with

breast adenocarcinoma
invasive breast cancer
HER2
platelet count
breast cancer
  • 0 views
  • 24 Jan, 2021
  • 6 locations
Clinical Trial of Atezolizumab With Paclitaxel Trastuzumab and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced

immunohistochemistry
ejection fraction
ct scan
paclitaxel
dexamethasone
  • 82 views
  • 09 Apr, 2020
  • 1 location
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.

immunohistochemistry
paclitaxel
invasive breast cancer
core needle biopsy
HER2
  • 8 views
  • 17 Sep, 2020
  • 42 locations
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.

primary tumor
progesterone receptor
magnetic resonance imaging of breast
breast cancer staging
progesterone
  • 89 views
  • 09 Sep, 2020
  • 15 locations
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate …

ejection fraction
bisphosphonate
cancer
inflammatory breast cancer
invasive breast cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
Omission of Radiation in Patients With Her-2 Positive Breast Cancer

The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.

breast cancer staging
breast cancer
ductal carcinoma
trastuzumab
her-2
  • 132 views
  • 24 Jan, 2021
  • 1 location